Research on CBD for over 50 Conditions

research on cbd - Research on CBD for 50+ Conditions - CBD Origin

“Is There Any Research on CBD?”

On a regular basis, readers will ask us a range of questions about CBD, and one of the most commonly asked questions is “Is there any research on CBD for (some condition)?

While the sudden explosion of interest into CBD has led many to assume that its health benefits are a recent breakthrough, CBD has actually been studied for decades

In fact, over the last century, researchers have evaluated CBD as a potential treatment for more than fifty conditions, with new studies being conducted every year.

If you’re looking for research on CBD by condition, you’ve come to the right place.

From arthritis and fibromyalgia to neurodegeneration, sleep disorders and beyond, we’ve compiled a comprehensive collection of more than 350 research articles on CBD and its effectiveness for the treatment of more than fifty conditions.

Check out the full collection of research articles below, and easily filter with the “Search by Condition” option.

Browse Medical Research Based on Condition

#GROUPCONDITIONMEDICAL RESEARCH
51CBD FOR ACNECannabidiol as a Treatment for Acne?
1CBD FOR ACNECannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
1CBD FOR ACNEThe endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities
1CBD FOR ACNEEndocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling
1CBD FOR ACNEEndocannabinoid signaling and epidermal differentiation
62CBD FOR ADD / ADHDSearching for a Neurobiological Basis for Self-Medication Theory in ADHD Comorbid With Substance Use Disorders
2CBD FOR ADD / ADHDCannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats
2CBD FOR ADD / ADHDSubtypes of Attention Deficit — Hyperactivity Disorder (ADHD) and cannabis use
2CBD FOR ADD / ADHDChildhood and current ADHD symptom dimensions are associated with more severe cannabis outcomes in college students
2CBD FOR ADD / ADHDOral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report
2CBD FOR ADD / ADHDFitness to drive in spite (because) of THC
103CBD FOR ADDICTIONCannabidiol reduces cigarette consumption in tobacco smokers
3CBD FOR ADDICTIONCannabidiol inhibits the reward-facilitating effect of morphine
3CBD FOR ADDICTIONCannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances
3CBD FOR ADDICTIONDifferential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats
3CBD FOR ADDICTIONImpact of Cannabis Use during Stabilization on Methadone Maintenance Treatment
3CBD FOR ADDICTIONMedical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010
3CBD FOR ADDICTIONDysregulation of cannabinoid CB1 receptor and associated signaling networks in brains of cocaine addicts and cocaine-treated rodents
3CBD FOR ADDICTIONComparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity
3CBD FOR ADDICTIONTransdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder
3CBD FOR ADDICTIONCannabidiol for the treatment of cannabis withdrawal syndrome
44CBD FOR ALSCannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials
4CBD FOR ALSALS: delayed disease progression in mice by treatment with a cannabinoid
4CBD FOR ALSThe (Endo)Cannabinoid System in Multiple Sclerosis and ALS
4CBD FOR ALSSurvey of cannabis use in patients with ALS
165CBD FOR ALZHEIMERSThe therapeutic potential of the endocannabinoid system for Alzheimer’s disease
5CBD FOR ALZHEIMERSEndocannabinoid signalling in Alzheimer’s disease
5CBD FOR ALZHEIMERSA molecular link between the active component of marijuana and Alzheimer’s disease pathology
5CBD FOR ALZHEIMERSNeuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells
5CBD FOR ALZHEIMERSThe Potential Therapeutic Effects of THC on Alzheimer’s Disease
5CBD FOR ALZHEIMERSThe Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease
5CBD FOR ALZHEIMERSCannabinoids for the treatment of dementia
5CBD FOR ALZHEIMERSCannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression
5CBD FOR ALZHEIMERSCannabidiol: A promising drug for neurodegenerative disorders?
5CBD FOR ALZHEIMERSCannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition
5CBD FOR ALZHEIMERSThe role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses
5CBD FOR ALZHEIMERSThe role of phytochemicals in the treatment and prevention of dementia
5CBD FOR ALZHEIMERSCannabinoids for the treatment of dementia
5CBD FOR ALZHEIMERSCannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement
5CBD FOR ALZHEIMERSCannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
5CBD FOR ALZHEIMERSCan Marijuana Prevent Alzheimer’s?
46CBD FOR ANOREXIALeptin, ghrelin, and endocannabinoids: Potential therapeutic targets in anorexia nervosa
6CBD FOR ANOREXIAThe role of the endocannabinoid system in eating disorders: Neurochemical and behavioural preclinical evidence
6CBD FOR ANOREXIACancer cachexia and cannabinoids
6CBD FOR ANOREXIABrain Type 1 Cannabinoid Receptor Availability in Patients with Anorexia and Bulimia Nervosa
97CBD FOR ANXIETYCannabidiol, a Cannabis sativa constituent, as an anxiolytic drug
7CBD FOR ANXIETYAntidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa
7CBD FOR ANXIETYCannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients
7CBD FOR ANXIETYNeural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder
7CBD FOR ANXIETYCentral anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation
7CBD FOR ANXIETYEffects of cannabidiol (CBD) on regional cerebral blood flow
7CBD FOR ANXIETYThe anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors
7CBD FOR ANXIETYThe anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
7CBD FOR ANXIETYPlant-based medicines for anxiety disorders, part 2: A review of clinical studies with supporting preclinical evidence
48CBD FOR ATHEROSCLEROSISThe role of the endocannabinoid system in atherosclerosis
8CBD FOR ATHEROSCLEROSISCannabinoid receptors in atherosclerosis
8CBD FOR ATHEROSCLEROSISThe potential use of cannabidiol in the therapy of metabolic syndrome
8CBD FOR ATHEROSCLEROSISLow dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
49CBD FOR ARTHRITISPreliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis
9CBD FOR ARTHRITISThe nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
9CBD FOR ARTHRITISThe abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55
9CBD FOR ARTHRITISArthritis and cannabinoids
510CBD FOR ASTHMAThe role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke
10CBD FOR ASTHMAAllergen challenge increases anandamide in bronchoalveolar fluid of patients with allergic asthma
10CBD FOR ASTHMAActivation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs
10CBD FOR ASTHMAEndogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways
10CBD FOR ASTHMABronchodilator effect of delta1-tetrahydrocannabinol
511CBD FOR AUTISMMutations found in individuals with autism interfere with endocannabinoid signaling in the brain
11CBD FOR AUTISMCannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders
11CBD FOR AUTISMA novel approach to the symptomatic treatment of autism
11CBD FOR AUTISMConsequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders
11CBD FOR AUTISMTargeting the endocannabinoid system in the treatment of fragile X syndrome
512CBD FOR BIPOLAR AFFECTIVE DISORDERCannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential
12CBD FOR BIPOLAR AFFECTIVE DISORDERCannabidiol was ineffective for manic episode of bipolar affective disorder
12CBD FOR BIPOLAR AFFECTIVE DISORDEREffects of Co-occurring Cannabis Use Disorders on the Course of Bipolar Disorder After a First Hospitalization for Mania
12CBD FOR BIPOLAR AFFECTIVE DISORDERDoes Cannabis Use Affect Treatment Outcome in Bipolar Disorder?: A Longitudinal Analysis
12CBD FOR BIPOLAR AFFECTIVE DISORDERThe Use of Cannabis as a Mood Stabilizer in Bipolar Disorder: Anecdotal Evidence and the Need for Clinical Research
513CBD FOR CANCER - GENERALCannabidiol as potential anticancer drug
13CBD FOR CANCER - GENERALCannabidiol inhibits angiogenesis by multiple mechanisms
13CBD FOR CANCER - GENERALThe inhibitory effects of cannabidiol on systemic malignant tumors
13CBD FOR CANCER - GENERALCannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1
13CBD FOR CANCER - GENERALMarijuana fights cancer and helps manage side effects
414CBD FOR CANCER - LUNGCannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1C
14CBD FOR CANCER - LUNGCOX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells
14CBD FOR CANCER - LUNGDecrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells
14CBD FOR CANCER - LUNGMedia ignored expert’s shocking findings that marijuana helps prevent lung cancer
515CBD FOR CANCER - PROSTATE/COLONTowards the use of non-psychoactive cannabinoids for prostate cancer
15CBD FOR CANCER - PROSTATE/COLONIn Vitro Anticancer Activity of Plant-Derived Cannabidiol on Prostate Cancer Cell Lines
15CBD FOR CANCER - PROSTATE/COLONInduction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent
15CBD FOR CANCER - PROSTATE/COLONChemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer
15CBD FOR CANCER - PROSTATE/COLONInhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol
516CBD FOR CANCER - BREASTAntitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma
16CBD FOR CANCER - BREASTCannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy
16CBD FOR CANCER - BREASTPathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis
16CBD FOR CANCER - BREASTCannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
16CBD FOR CANCER - BREASTCannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration
817CBD FOR CANCER - BRAINCannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival
17CBD FOR CANCER - BRAINAntitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines(PubMed)
17CBD FOR CANCER - BRAINSystematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas
17CBD FOR CANCER - BRAINCannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism
17CBD FOR CANCER - BRAINId-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target
17CBD FOR CANCER - BRAINTriggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents
17CBD FOR CANCER - BRAINCannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect
17CBD FOR CANCER - BRAINLocal delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme
418CBD FOR CANCER - LEUKEMIACannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression
18CBD FOR CANCER - LEUKEMIACannabidiol-Induced Apoptosis in Human Leukemia Cells
18CBD FOR CANCER - LEUKEMIACannabidiol Reduces Leukemic Cell Size – But Is It Important?
18CBD FOR CANCER - LEUKEMIATargeting cannabinoid receptors to treat leukemia
419CBD FOR CANCER - SKINAnticancer activity of anandamide in human cutaneous melanoma cells
19CBD FOR CANCER - SKINCannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpes virus-infected endothelium (PubMed)
19CBD FOR CANCER - SKINCannabinoid receptors as novel targets for the treatment of melanoma
19CBD FOR CANCER - SKINThe Cannabinoid Receptors Are Required for Ultraviolet-Induced Inflammation and Skin Cancer Development
420CBD FOR CANCER - ENDOCRINEEndocannabinoids in endocrine and related tumours
20CBD FOR CANCER - ENDOCRINEA comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells
20CBD FOR CANCER - ENDOCRINECannabinoids in pancreatic cancer: Correlation with survival and pain
20CBD FOR CANCER - ENDOCRINECannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma
421CBD FOR CANCER - BLADDERTRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer
21CBD FOR CANCER - BLADDERAssociation Between Cannabis Use and the Risk of Bladder Cancer
21CBD FOR CANCER - BLADDERInhibitory Effect of Standardized Cannabis sativaExtract and Its Ingredient Cannabidiol on Rat and Human Bladder Contractility
21CBD FOR CANCER - BLADDERBladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism
422CBD FOR CANCER - PAIN RELIEFMulticenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain
22CBD FOR CANCER - PAIN RELIEFNabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial
22CBD FOR CANCER - PAIN RELIEFMarijuana extract helps prevent chemo pain
22CBD FOR CANCER - PAIN RELIEFAn Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics
1023CBD FOR CROHNS & COLITISCannabidiol in inflammatory bowel diseases: a brief overview
23CBD FOR CROHNS & COLITISCannabis finds its way into treatment of Crohn’s disease
23CBD FOR CROHNS & COLITISCannabidiol reduces intestinal inflammation through the control of neuroimmune axis
23CBD FOR CROHNS & COLITISCannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
23CBD FOR CROHNS & COLITISThe effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis
23CBD FOR CROHNS & COLITISTopical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice
23CBD FOR CROHNS & COLITISCannabinoids and the gut: New developments and emerging concepts
23CBD FOR CROHNS & COLITISEndocannabinoids and the gastrointestinal tract
23CBD FOR CROHNS & COLITISCannabinoids and gastrointestinal motility: Animal and human studies
23CBD FOR CROHNS & COLITISHergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis
1124CBD FOR DEPRESSIONEndocannabinoid system dysfunction in mood and related disorders
24CBD FOR DEPRESSIONAntidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa
24CBD FOR DEPRESSIONThe endocannabinoid system and the treatment of mood and anxiety disorders
24CBD FOR DEPRESSIONEndocannabinoid signaling in the etiology and treatment of major depressive illness
24CBD FOR DEPRESSIONAntidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors
24CBD FOR DEPRESSIONPutative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants
24CBD FOR DEPRESSIONAntidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa
24CBD FOR DEPRESSIONCirculating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress
24CBD FOR DEPRESSIONSerum contents of endocannabinoids are correlated with blood pressure in depressed women
24CBD FOR DEPRESSIONThe therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants
24CBD FOR DEPRESSIONAntidepressants and Changes in Concentration of Endocannabinoids and N-Acylethanolamines in Rat Brain Structures
2125CBD FOR ENDOCRINE DISORDERSEndocannabinoid system participates in neuroendocrine control of homeostasis
25CBD FOR ENDOCRINE DISORDERSThe emerging role of the endocannabinoid system in endocrine regulation and energy balance
25CBD FOR ENDOCRINE DISORDERSEndocannabinoids in endocrine and related tumours
25CBD FOR ENDOCRINE DISORDERSRole of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas
25CBD FOR ENDOCRINE DISORDERSThe role of the endocannabinoid system in the neuroendocrine regulation of energy balance
25CBD FOR ENDOCRINE DISORDERSCBD for children with Dravet’s and intractable seizures
25CBD FOR ENDOCRINE DISORDERSReport of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy
25CBD FOR ENDOCRINE DISORDERSMedicinal marijuana stops seizures, brings hope to a little girl
25CBD FOR ENDOCRINE DISORDERSCannabinoids for epilepsy
25CBD FOR ENDOCRINE DISORDERSCannabis, cannabidiol, and epilepsy – From receptors to clinical response
25CBD FOR ENDOCRINE DISORDERSThe non-psychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability
25CBD FOR ENDOCRINE DISORDERSChronic administration of cannabidiol to healthy volunteers and epileptic patients
25CBD FOR ENDOCRINE DISORDERSEndocannabinoid system protects against cryptogenic seizures
25CBD FOR ENDOCRINE DISORDERSSeizing an opportunity for the endocannabinoid system
25CBD FOR ENDOCRINE DISORDERSCannabidiol: promise and pitfalls
25CBD FOR ENDOCRINE DISORDERSCannabidivarin (CBDV) suppressespentylenetetrazole (PTZ)-inducedincreases in epilepsy-related gene expression
25CBD FOR ENDOCRINE DISORDERSCannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures
25CBD FOR ENDOCRINE DISORDERSCannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo
25CBD FOR ENDOCRINE DISORDERSHypnotic and antiepileptic effects of cannabidiol
25CBD FOR ENDOCRINE DISORDERSThe cannabinoids as potential antiepileptics
25CBD FOR ENDOCRINE DISORDERSCannabidiol–antiepileptic drug comparisons and interactions in experimentally induced seizures in rats
526CBD FOR FIBROMYALGIAClinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
26CBD FOR FIBROMYALGIACannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life
26CBD FOR FIBROMYALGIAAssociation of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia
26CBD FOR FIBROMYALGIACannabinoids for fibromyalgia
26CBD FOR FIBROMYALGIAMedical Cannabis for the Treatment of Fibromyalgia
427CBD FOR GLAUCOMANeuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite
27CBD FOR GLAUCOMACannabinoids and glaucoma
27CBD FOR GLAUCOMAThe treatment of glaucoma using a non-psychoactive preparation of Cannabis sativa
27CBD FOR GLAUCOMACannabinoids for treatment of glaucoma
728CBD FOR HEART DISEASEIs the cardiovascular system a therapeutic target for cannabidiol?
28CBD FOR HEART DISEASEAcute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion
28CBD FOR HEART DISEASECannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy
28CBD FOR HEART DISEASEThe Effect of Cannabidiol on Ischemia/Reperfusion-Induced Ventricular Arrhythmias: The Role of Adenosine A1 Receptors
28CBD FOR HEART DISEASECannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury
28CBD FOR HEART DISEASEEndocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension
28CBD FOR HEART DISEASEOleamide: A fatty acid amide signaling molecule in the cardiovascular system?
629CBD FOR HUNTINGTONS DISEASENeuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease
29CBD FOR HUNTINGTONS DISEASECannabinoids: Novel medicines for the treatment of Huntington’s disease
29CBD FOR HUNTINGTONS DISEASESativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB(1) and CB(2) receptors
29CBD FOR HUNTINGTONS DISEASEControlled clinical trial of cannabidiol in Huntington’s disease
29CBD FOR HUNTINGTONS DISEASEProspects for cannabinoid therapies in basal ganglia disorders
29CBD FOR HUNTINGTONS DISEASENeuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice
1330CBD FOR INFLAMMATIONCannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress
30CBD FOR INFLAMMATIONThe endocannabinoid system: an emerging key player in inflammation
30CBD FOR INFLAMMATIONAnti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice
30CBD FOR INFLAMMATIONCannabinoids, endocannabinoids, and related analogs in inflammation
30CBD FOR INFLAMMATIONCannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor
30CBD FOR INFLAMMATIONCannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
30CBD FOR INFLAMMATIONCannabidiol reduces intestinal inflammation through the control of neuroimmune axis
30CBD FOR INFLAMMATIONDiabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation
30CBD FOR INFLAMMATIONCannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement
30CBD FOR INFLAMMATIONCannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption
30CBD FOR INFLAMMATIONVanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
30CBD FOR INFLAMMATIONCannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death
30CBD FOR INFLAMMATIONCannabinoids in clinical practice
931CBD FOR IRRITABLE BOWEL SYNDROMECannabidiol in inflammatory bowel diseases: A brief overview
31CBD FOR IRRITABLE BOWEL SYNDROMECannabidiol reduces intestinal inflammation through the control of neuroimmune axis
31CBD FOR IRRITABLE BOWEL SYNDROMEClinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
31CBD FOR IRRITABLE BOWEL SYNDROMECannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
31CBD FOR IRRITABLE BOWEL SYNDROMETherapeutic potential of cannabinoid-based drugs
31CBD FOR IRRITABLE BOWEL SYNDROMEBeneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology)
31CBD FOR IRRITABLE BOWEL SYNDROMECannabinoids and the gut: New developments and emerging concepts
31CBD FOR IRRITABLE BOWEL SYNDROMEEndocannabinoids and the gastrointestinal tract
31CBD FOR IRRITABLE BOWEL SYNDROMECannabinoids and gastrointestinal motility: Animal and human studies
432CBD FOR KIDNEY DISEASECannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death
32CBD FOR KIDNEY DISEASEChronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay
32CBD FOR KIDNEY DISEASEIs There a Legitimate Role for the Therapeutic Use of Cannabinoids for Symptom Management in Chronic Kidney Disease?
32CBD FOR KIDNEY DISEASEThe emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases
733CBD FOR LIVER DISEASEThe endocannabinoid system and liver diseases
33CBD FOR LIVER DISEASECannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death
33CBD FOR LIVER DISEASECannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis
33CBD FOR LIVER DISEASETherapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats
33CBD FOR LIVER DISEASERole of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol
33CBD FOR LIVER DISEASECannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice
33CBD FOR LIVER DISEASECannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation
534CBD FOR METABOLIC SYNDROMEThe impact of marijuana use on glucose, insulin, and insulin resistance among US adults
34CBD FOR METABOLIC SYNDROMEThe potential use of cannabidiol in the therapy of metabolic syndrome
34CBD FOR METABOLIC SYNDROMECannabinoids and endocannabinoids in metabolic disorders with focus on diabetes
34CBD FOR METABOLIC SYNDROMEMetabolic syndrome in people with a psychotic illness: is cannabis protective?
34CBD FOR METABOLIC SYNDROMECannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome
535CBD FOR MIGRAINESClinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
35CBD FOR MIGRAINESEffects of anandamide in migraine: data from an animal model
35CBD FOR MIGRAINESCannabinoids and hallucinogens for headache
35CBD FOR MIGRAINESThe endocannabinoid system and migraine
35CBD FOR MIGRAINESVariations in the cannabinoid receptor 1 gene predispose to migraine
636CBD FOR MOOD DISORDERSMultiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
36CBD FOR MOOD DISORDERSThe endocannabinoid system and the treatment of mood and anxiety disorders
36CBD FOR MOOD DISORDERSThe endocannabinoid system and psychiatric disorders
36CBD FOR MOOD DISORDERSThe endocannabinoid system in the regulation of emotions throughout lifespan: A discussion on therapeutic perspectives
36CBD FOR MOOD DISORDERSEndocannabinoid system dysfunction in mood and related disorders
36CBD FOR MOOD DISORDERSEffects of cannabidiol (CBD) on regional cerebral blood flow
337CBD FOR MOTION SICKNESSMotion sickness, stress and the endocannabinoid system
37CBD FOR MOTION SICKNESSDexamethasone alleviates motion sickness in rats in part by enhancing the endocannabinoid system
37CBD FOR MOTION SICKNESSThe Effects of Cannabidiol and Tetrahydrocannabinol on Motion‐Induced Emesis
1038CBD FOR MULTIPLE SCLEROSISSativex for the management of multiple sclerosis symptoms
38CBD FOR MULTIPLE SCLEROSISTHC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis
38CBD FOR MULTIPLE SCLEROSISClinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity
38CBD FOR MULTIPLE SCLEROSISCannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
38CBD FOR MULTIPLE SCLEROSISOromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial
38CBD FOR MULTIPLE SCLEROSISNabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis
38CBD FOR MULTIPLE SCLEROSISSativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis
38CBD FOR MULTIPLE SCLEROSISA double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
38CBD FOR MULTIPLE SCLEROSISMeta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain(
38CBD FOR MULTIPLE SCLEROSISSativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
639CBD FOR NAUSEACannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus
39CBD FOR NAUSEACannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation
39CBD FOR NAUSEAInteraction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews
39CBD FOR NAUSEARegulation of nausea and vomiting by cannabinoids
39CBD FOR NAUSEACannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats
39CBD FOR NAUSEAPreliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting
540CBD FOR NEURODEGENERATIONCannabidiol: A promising drug for neurodegenerative disorders?
40CBD FOR NEURODEGENERATIONCannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?
40CBD FOR NEURODEGENERATIONTransdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder
40CBD FOR NEURODEGENERATIONMemory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders
40CBD FOR NEURODEGENERATIONCannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection
1841CBD FOR NEUROPATHIC PAINMeta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
41CBD FOR NEUROPATHIC PAINSativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
41CBD FOR NEUROPATHIC PAINCannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine
41CBD FOR NEUROPATHIC PAINSativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial
41CBD FOR NEUROPATHIC PAINCannabinoids for neuropathic pain
41CBD FOR NEUROPATHIC PAINNeuropathic orofacial pain: Cannabinoids as a therapeutic avenue
41CBD FOR NEUROPATHIC PAINOromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial
41CBD FOR NEUROPATHIC PAINThe non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
41CBD FOR NEUROPATHIC PAINVanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
41CBD FOR NEUROPATHIC PAINCannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy
41CBD FOR NEUROPATHIC PAINAntihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: Mechanisms involved
41CBD FOR NEUROPATHIC PAINNon-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action
41CBD FOR NEUROPATHIC PAINCannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
41CBD FOR NEUROPATHIC PAINRole of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes
41CBD FOR NEUROPATHIC PAINCannabinoids in the management of difficult to treat pain
41CBD FOR NEUROPATHIC PAINMulticenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain
41CBD FOR NEUROPATHIC PAINMarijuana extract helps prevent chemo pain
41CBD FOR NEUROPATHIC PAINPot users less likely to take painkillers
642CBD FOR OBESITYThe impact of marijuana use on glucose, insulin, and insulin resistance among US adults
42CBD FOR OBESITYCannabinol and cannabidiol exert opposing effects on rat feeding patterns
42CBD FOR OBESITYCannabis and Δ9-tetrahydrocannabinol (THC) for weight loss?
42CBD FOR OBESITYThe endocannabinoid system in obesity and type 2 diabetes
42CBD FOR OBESITYRole of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk
42CBD FOR OBESITYCannabinoids and endocannabinoids in metabolic disorders with focus on diabetes
343CBD FOR OCDPlasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour (PubMed)
43CBD FOR OCDPlasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour
43CBD FOR OCDInvolvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice
744CBD FOR PARKINSONS DISEASEEffects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial
44CBD FOR PARKINSONS DISEASEProspects for cannabinoid therapies in basal ganglia disorders
44CBD FOR PARKINSONS DISEASEEvaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: Importance of antioxidant and cannabinoid receptor-independent properties
44CBD FOR PARKINSONS DISEASECannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease
44CBD FOR PARKINSONS DISEASECannabidiol for the treatment of psychosis in Parkinson’s disease
44CBD FOR PARKINSONS DISEASESymptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease
44CBD FOR PARKINSONS DISEASETherapeutic potential of cannabinoids in CNS disease
345CBD FOR PRIONNonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity
45CBD FOR PRIONCannabidiol: A prion therapy for mice?
45CBD FOR PRIONAlteration of the endocannabinoid system in mouse brain during prion disease
1346CBD FOR PTSDThe endocannabinoid system provides an avenue for evidence-based treatment development for PTSD
46CBD FOR PTSDReductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks
46CBD FOR PTSDEnhancing cannabinoid neurotransmission augments the extinction of conditioned fear
46CBD FOR PTSDCannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors
46CBD FOR PTSDStress switches cannabinoid type-1 (CB1) receptor-dependent plasticity from LTD to LTP in the bed nucleus of the stria terminalis
46CBD FOR PTSDMitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence
46CBD FOR PTSDCannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment
46CBD FOR PTSDThe endocannabinoid system and extinction learning
46CBD FOR PTSDA current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers
46CBD FOR PTSDCannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit
46CBD FOR PTSDNon-antidepressant long-term treatment in post-traumatic stress disorder
46CBD FOR PTSDThe anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system
46CBD FOR PTSDModulation of Fear Memory by Dietary Polyunsaturated Fatty Acids via Cannabinoid Receptors
447CBD FOR RHEUMATISMCannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress
47CBD FOR RHEUMATISMEfficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases
47CBD FOR RHEUMATISMClinical Implications for Cannabinoid Use in the Rheumatic Diseases
47CBD FOR RHEUMATISMCannabinoids in the Management of Musculoskeletal or Rheumatic Diseases
1248CBD FOR SCHIZOPHRENIACannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
48CBD FOR SCHIZOPHRENIACannabidiol as a potential treatment for psychosis
48CBD FOR SCHIZOPHRENIACannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
48CBD FOR SCHIZOPHRENIAMedical use of cannabis. Cannabidiol: A new light for schizophrenia?
48CBD FOR SCHIZOPHRENIAA critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation
48CBD FOR SCHIZOPHRENIAPeripheral endocannabinoid system dysregulation in first-episode psychosis
48CBD FOR SCHIZOPHRENIACannabinoids and schizophrenia: Therapeutic prospects
48CBD FOR SCHIZOPHRENIAAntipsychotic-like effects of cannabidiol and rimonabant: Systematic review of animal and human studies
48CBD FOR SCHIZOPHRENIACannabidiol monotherapy for treatment-resistant schizophrenia
48CBD FOR SCHIZOPHRENIACannabis with high cannabidiol content is associated with fewer psychotic experiences
48CBD FOR SCHIZOPHRENIAMarijuana compound treats schizophrenia with few side effects: Clinical trial
48CBD FOR SCHIZOPHRENIAClearing the smoke: what do we know about adolescent cannabis use and schizophrenia?
349CBD FOR SICKLE CELL ANEMIAPain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: Modulation by cannabinoids
49CBD FOR SICKLE CELL ANEMIACannabis use in sickle cell disease: A questionnaire study
49CBD FOR SICKLE CELL ANEMIACannabinoid Receptor-Specific Mechanisms To Alleviate Pain In Sickle Cell Anemia Via Inhibition Of Mast Cell Activation And Neurogenic Inflammation
850CBD FOR SKIN CONDITIONSCannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis
50CBD FOR SKIN CONDITIONSCannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
50CBD FOR SKIN CONDITIONSThe endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities
50CBD FOR SKIN CONDITIONSEpigenetic control of skin differentiation genes by phytocannabinoids
50CBD FOR SKIN CONDITIONSEndocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1
50CBD FOR SKIN CONDITIONSCannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation
50CBD FOR SKIN CONDITIONSAttenuation of allergic contact dermatitis through the endocannabinoid system
50CBD FOR SKIN CONDITIONSTopical cannabinoid agonists. An effective new possibility for treating chronic pruritus
751CBD FOR SLEEP DISORDERSThe nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent
51CBD FOR SLEEP DISORDERSCannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine
51CBD FOR SLEEP DISORDERSEffects of acute systemic administration of cannabidiol on sleep-wake cycle in rats
51CBD FOR SLEEP DISORDERSEffect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults
51CBD FOR SLEEP DISORDERSCannabidiol, a constituent of Cannabis sativa, modulates sleep in rats
51CBD FOR SLEEP DISORDERSEndocannabinoid modulation of cortical up-states and NREM sleep
51CBD FOR SLEEP DISORDERSIntranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat
452CBD FOR SPINAL CORD INJURYCannabidiol-treated rats exhibited higher motor score after cryogenic spinal cord injury
52CBD FOR SPINAL CORD INJURYCannabis effect on spasticity in spinal cord injury
52CBD FOR SPINAL CORD INJURYAn Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease
52CBD FOR SPINAL CORD INJURYModulation of Inflammatory Responses by a Cannabinoid-2–Selective Agonist after Spinal Cord Injury
1353CBD FOR STRESSEndogenous cannabinoid signaling is essential for stress adaptation
53CBD FOR STRESSRegulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders
53CBD FOR STRESSFunctional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output
53CBD FOR STRESSNeuromodulators, stress and plasticity: a role for endocannabinoid signalling
53CBD FOR STRESSDownregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress
53CBD FOR STRESSEndocannabinoids and stress
53CBD FOR STRESSStress regulates endocannabinoid-CB1 receptor signaling
53CBD FOR STRESSChronic Stress Impairs α1-Adrenoceptor-Induced Endocannabinoid-Dependent Synaptic Plasticity in the Dorsal Raphe Nucleus
53CBD FOR STRESSEndocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance
53CBD FOR STRESSCannabinoid receptor activation prevents the effects of chronic mild stress on emotional learning and LTP in a rat model of depression
53CBD FOR STRESSCannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory
53CBD FOR STRESSThe anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
53CBD FOR STRESSLow-frequency stimulation evokes serotonin release in the nucleus accumbens and induces long-term depression via production of endocannabinoid
654CBD FOR STROKE/TBICannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury
54CBD FOR STROKE/TBICannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism
54CBD FOR STROKE/TBICannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism (
54CBD FOR STROKE/TBICannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function
54CBD FOR STROKE/TBIProtective Effects of Cannabidiol Against Hippocampal Cell Death and Cognitive Impairment Induced by Bilateral Common Carotid Artery Occlusion in Mice
54CBD FOR STROKE/TBIRepeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance
Thanks for being a part of our community! We hope that this repository has served as a valuable resource in your journey to learn about CBD.

Please help us spread the word about the many benefits of CBD by sharing this resource with anyone wonder if CBD can benefit any specific condition.

Login to Your Account

Join Our Community

Retrieve your password

Please enter your username or email address to reset your password.